Declaration of interests MN declares payment for advisory board participation and consultation for Akero, Altimmune, Alligos, AstraZeneca, Boehringer Ingelheim, Boston Pharma, Curve bioscience, Daiichi Sankyo, GSK, Histoindex, Kryia, Lilly, Madrigal, Merck, Neuraly, Novo Nordisk, OPKO, Rivus, Sagimet, and Takeda; being a principal investigator for a drug study for Allergan, Altimmune, Akero, BI, Bristol Myers Squibb, Boston Pharma, Conatus, Corcept, Enanta, Gilead, Galectin, Genfit, GSK, Kowa, Lilly, Madrigal, Merck, Novartis, Novo Nordisk, Rivus, Shire, Takeda, Terns, Viking, and Zydus; owns stock of OPKO, Kryia, and Akero; and is a member of the speakers bureaus for Madrigal, BI, and Novo Nordisk. WD reports grants from 89Bio, NATiV3, Novo Nordisk, and Madrigal Pharmaceuticals; is a member of the speakers bureaus for Novo Nordisk and Madrigal Pharmaceuticals; and is an advisor for Ipsen Biopharmaceuticals. RPa has received research funding via investigator grants from Akero Therapeutics, Boehringer Ingelheim, Eli Lilly, Madrigal Pharmaceuticals, Merck, Novo Nordisk, 89Bio, and Inventiva; has received consulting or advisory fees from Boehringer Ingelheim and Novo Nordisk; and is on the speakers bureau for Novo Nordisk and Madrigal Pharmaceuticals. JS is employed by D&D Pharmatech, Neuraly; has a licensing agreement with Salubris Pharmaceuticals (for which no funds were received during the previous 36 months); is listed as an inventor on the patent for DD01 and associated technologies; and owns stock and stock options in D&D Pharmatech, Neuraly. DT and ACB are employed by and own stock options in D&D Pharmatech, Neuraly. DRL, Y-HL, and SL are employed by D&D Pharmatech, Neuraly. RPu and DD declare no competing interests.
PubMed
